Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial

Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial Prof Anwen Xiong, MDa,* ∙ Prof Wenxiu Yao, MDb,* ∙ Prof Wei Zheng, MDc,* ∙ Yan Yu* ∙ Peng Chen, MDe,* ∙ Prof Hua Zhong, MDf,* ∙ et al. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00968-2/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_asco26&_hsenc=p2ANqtz-_1h5vEtu4pLpKadWtqaVc7nT_ajP697uA04ByYzhu8Wy_q326x-Y1guSBgDH-se3sYUyDsd_BeC4t6EvdDIuuNNEEbdw&_hsmi=421795296&utm_content=421795296&utm_source=hs_email